版權說明:本文檔由用戶提供并上傳,收益歸屬內容提供方,若內容存在侵權,請進行舉報或認領
文檔簡介
1、新藥安全藥理學研究與進展,第二軍醫(yī)大學藥物安全性評價中心 陸國才 袁伯俊,,,內 容,安全藥理學:研究藥物治療范圍內或治療范圍以上的劑量時,潛在不期望出現(xiàn)的對生理功能的不良影響次要藥效學:主要研究藥物非期望的、與治療目的不相關的效應和作用機制,,概 念,SFDA要求,核心組合試驗(Core Battery) 中樞神經(jīng)系統(tǒng)、心血管系統(tǒng)和呼吸系統(tǒng)研究追加的安全藥理學研究(Follow-up) 對中樞神經(jīng)系統(tǒng)、心血管系
2、統(tǒng)和呼吸系統(tǒng)進行深入的研究 補充的安全藥理學研究(Supplemental) 研究藥物對三大系統(tǒng)以外器官(如泌尿系統(tǒng)、自主神經(jīng)系統(tǒng)、胃腸道系統(tǒng)和其它器官組織)功能的影響,,概 念,SFDA要求,確定藥物可能存在的非期望藥效作用評價藥物在毒理學和/或臨床研究中所觀察到的藥物不良反應和/或病理生理作用研究所觀察到的和/或推測的藥物不良反應機制,,目 的,SFDA要求,有助于了解新藥的藥理作用特點和機制有助于發(fā)現(xiàn)新藥理作用
3、,一藥多用,藥盡其用為毒理學研究打下基礎,是各種毒性實驗的必要補充,,目 的,SFDA要求,貫穿在新藥研究全過程中,可分階段進行在藥物進入臨床試驗前,應完成Core Battery Studies追加和/或補充的安全藥理學研究可在申報生產(chǎn)前進行,,階段性,SFDA要求,,內容要求,SFDA要求,神經(jīng)系統(tǒng) 運動功能、行為改變、協(xié)調功能、感覺運動反射和體溫等的變化(小鼠)心血管系統(tǒng) 給藥前后血壓(包括收縮壓、舒張壓和平均
4、壓)、心電圖(包括QT間期、PR間期、ST段和QRS波等)和心率等變化(Beagle犬)呼吸系統(tǒng) 呼吸頻率和呼吸幅度(Beagle犬)根據(jù)情況增加其它系統(tǒng)或指標,1.動物選擇 可采用不同類型動物(正?;蚰P?,清醒或麻醉)。一般多用正常動物2.劑量途徑 產(chǎn)生主要藥效作用及以上的3個劑量,臨床給藥途徑3.觀察時間 藥效學和藥代動力學特性、受試動物、臨床研究方案等因素選擇觀察時間點和觀察時間,SFDA要求,,有關問題,
5、4.系統(tǒng)指標中樞神經(jīng)系統(tǒng)心血管系統(tǒng)呼吸系統(tǒng)根據(jù)情況增加其它系統(tǒng)或指標5.體外研究 應確定受試物的濃度-效應關系。無明顯影響作用時,應說明濃度選擇范圍,SFDA要求,,有關問題,中樞神經(jīng)系統(tǒng):對行為、學習記憶、神經(jīng)生化、視覺、聽覺和電生理等的影響心血管系統(tǒng):對心輸出量、心肌收縮作用、血管阻力等指標的檢測呼吸系統(tǒng):對氣道阻力、肺動脈壓力、血氣分析等指標的檢測,SFDA要求,,追加安全藥理學,泌尿系統(tǒng):對腎功能的影響,如對尿
6、量、比重、滲透壓、pH、電解質平衡、蛋白質、細胞和血生化(如尿素氮、肌酐、蛋白質)等指標的檢測自主神經(jīng)系統(tǒng):有關受體的結合、體內或體外對激動劑或拮抗劑的功能反應、對自主神經(jīng)的直接刺激作用和對心血管反應、壓力反射和心率等指標的檢測,SFDA要求,,補充安全藥理學,胃腸系統(tǒng):觀察藥物對胃腸系統(tǒng)的影響,如胃液分泌量和pH、胃腸損傷、膽汁分泌、離體回腸收縮、胃液pH等指標的測定其它研究:潛在的依賴性、骨骼肌、免疫和內分泌功能等的影響,SFD
7、A要求,,補充安全藥理學,體內血藥濃度低,或其它組織器官分布很少的局部用藥(如皮膚、眼科用藥)只用于治療晚期癌癥病人的細胞毒類藥物,在首次用于臨床前可不做一般藥理學研究,但不包括具有新作用機制的此類藥物,SFDA要求,,免做安全藥理學,,,內 容,“Safety pharmacology includes the assessment of effects on vital functions, such as cardiova
8、scular, central nervous system and respiratory systems, and these should be evaluated prior to human exposure.” ICH M3: Nonclinical safety studies for the conduct of human clinical trials for pharmaceuticals. (Jul
9、y 1997)Value of safety pharmacology acknowledged by regulators and sponsors,ICH要求,,ICH Guideline M3, 1997,“[Safety pharmacology studies] .. investigate the potential for undesirable pharmacological activity in appropr
10、iate animal models and, where necessary, to incorporate particular monitoring for these activities in the toxicity studies and/or clinical studies.”“.. these studies may allow for a mechanistically-based explanation of
11、 specific organ toxicities, which should be considered carefully with respect to human use and indication(s).”ICH S6 “Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals” (Jul
12、y 1997)Pharmacological activity in animals should be considered in toxicology and clinical studiesMechanism-based understanding of toxicities (or pharmacological activities) should be carefully considered in the risk a
13、ssessment,ICH要求,,ICH Guideline S6, 1997,“This guidance was developed to help protect clinical trial participants and patients receiving marketed products from potential adverse effects of pharmaceuticals, while avoiding
14、unnecessary use of animals and other resources.”ICH S7A “Safety Pharmacology Studies for Human Pharmaceuticals” (July 2001)Safety pharmacology studies have the potential to reduce use of animals and other r
15、esources,ICH要求,,ICH Guideline S7A, 2001,清醒動物----遙測系統(tǒng),檢測清醒狀態(tài)下、自由活動動物的安全藥理學指標 節(jié)省動物符合動物福利要求適合不同給藥方式連續(xù)動態(tài)、長時間檢測指標,,ICH要求,,4 x 4拉丁方實驗設計,ICH要求,,4 x 8拉丁方實驗設計,ICH要求,Drug to increase gastrointestinal (GI) motilityOver 5.4 mil
16、lion prescriptions in 1996 (US)34 patients TdP, 23 long QT (1993-1996) Cardiotoxicity reported when used with Ketoconazole and/or ErythromycinCase report of 8-year old girl–intensive care,ICH要求,,Cisapride Story,ICH要求,
17、,Drug Interactions Leading to QT?,Drug to increase gastrointestinal (GI) motilityOver 5.4 million prescriptions in 1996 (US)34 patients TdP, 23 long QT 1993-1996 Cardiotoxicity reported when used with Ketoconazole and
18、/or ErythromycinCase report of 8-year old girl–intensive care4 deaths and 16 resuscitated from 1993 to 1996Drug withdrawn from US market –July, 2000,ICH要求,,Cisapride Story,FDA recommended removal of Terfenadine contai
19、ning products from the market in 01/1997FDA issued warning letter to Doctors about cardiac safety of CisapridePost-marketing surveillance became more important – Medwatch reporting systemSafety pharmacology guidances
20、were approved to look at cardiovascular, respiratory and CNS side-effects of drug candidates –ICH S7A and S7BScreening for QT prolongation is now an integral part of drug development (lead optimization to clinical),ICH要
21、求,,Regulatory Response,“The study results can be used to elucidate the mechanism of action and, when considered with other information, estimate risk for delayed ventricular repolarization and QT interval prolongation in
22、 humans.”ICH S7B: Nonclinical Evaluation of the Potential for Delayed Ventricular Repolarization (QT Interval Prolongation) by Human Pharmaceuticals (October 2005)Mechanism of action can be a goal of studiesUse
23、 data with other data to estimate risk for QT prolongation in humans,ICH要求,ICH Guideline S7B, 2005,,Bazett: QTc = QT / RR 0.5 Fridericia: QTc = QT / RR 0.33,ICH要求,QTc Interval,,心肌動作電位時的離子通道,,ICH要求,IKr: 快速延遲整流K+電流,QT/
24、QTc Prolongation,IKr Inhibition,Delayed Ventricular Repolarization,Arrhythmia,,,ADDITIONAL RISK FACTORS,,,IKr inhibitory potency: can help predict risk of QT/QTc prolongation is a biomarker for increased risk of
25、Ventricular Arrhythmias is not a biomarker for Torsade de Pointes,ICH要求,IKr &TdP,,ICH要求,Early after-depolarization(早后去極化)? TdP,,Drug Class Date WithdrawnTerfenadineAntihistamineFeb 1998SertindoleA
26、ntipsychoticDec 1998AstemizoleAntihistamineJun 1999Grepafloxacin AntibioticNov 1999CisaprideGI ProkineticJuly 2000,ICH要求,Drugs Withdrawn for TdP risk,,采用離體動物或人體心臟細胞、培養(yǎng)心臟細胞系或克隆人離子通道的異種表達體系測定離子流在離體
27、心臟標本進行動作電位參數(shù)測定,或在麻醉動物中進行能體現(xiàn)動作電位周期的特異性電生理參數(shù)檢測測定清醒或麻醉動物的ECG參數(shù)在離體心臟標本或動物進行致心律失常作用測定,QT間期延長非臨床研究方法,,ICH要求,,,內 容,2009,趨勢展望,安全藥理學政策法規(guī)不斷完善,,趨勢展望,QT間期研究策略,,體外電生理IKr研究采用原代或表達的IKr通道蛋白(如由hERG編碼的蛋白)評價藥物對離子電流的影響體內對QT的研究從體內測定心
28、室復極化,如QT間期檢測結果進行評價化學/藥理的分類可誘導人QT間期延長作用的藥物如抗精神病類藥物,組胺H-1受體拮抗劑、氟喹酮類,QT間期研究策略,,趨勢展望,追加試驗離體心臟 麻醉動物 重復給藥試驗動物種屬和性別的選擇用代謝性誘導劑或用拮抗劑用陽性藥和參比化合物其他通道的抑制作用在多個時間點測定電生理參數(shù)模擬病理狀況和心律失常綜合風險評估,QT間期研究策略,,趨勢展望,計算機模擬 (in silico
29、)干細胞定向分化為心肌細胞下丘腦病理切片HERG通道體外篩選新方法熒光篩選(測量膜電位)結合試驗 (標記的HERG通道阻滯劑,HTS)斑馬魚HTS結合藥代/藥效,研究毒理學生物標志,預測臨床,安全藥理學研究新技術新方法,,趨勢展望,計算機模擬 (in silico)干細胞定向分化為心肌細胞下丘腦病理切片HERG通道體外篩選新方法熒光篩選(測量膜電位)結合試驗 (標記的HERG通道阻滯劑,HTS)斑馬魚HTS結
30、合藥代/藥效,研究毒理學生物標志,預測臨床,安全藥理學研究新技術新方法,,趨勢展望,PART I MUTAGENESIS AND MUTANTSHighly Efficient ENU Mutagenesis in ZebrafishProduction of Pseudotyped Retrovirus and the Generation of Proviral Transgenic Zebrafi
31、shUndertaking a Successful Gynogenetic Haploid Screen in ZebrafishCryopreservation and In Vitro Fertilization at the Zebrafish International Resource Center,計算機模擬 (in silico)干細胞定向分化為心肌細胞下丘腦病理切片HERG通道體外篩選新方法熒光篩選(測量膜
32、電位)結合試驗 (標記的HERG通道阻滯劑,HTS)斑馬魚HTS結合藥代/藥效,研究毒理學生物標志,預測臨床,安全藥理學研究新技術新方法,,趨勢展望,PART II TRANSGENESISTransient and Stable Transgenesis Using Tol2 Transposon VectorsAnalysis of Genes and Genome by the Tol2-Mediated Gene
33、and Enhancer Trap MethodsBacterial Artificial Chromosome Transgenesis for ZebrafishSimple and Efficient Transgenesis with Meganuclease Constructs in Zebrafish,計算機模擬 (in silico)干細胞定向分化為心肌細胞下丘腦病理切片HERG通道體外篩選新方法熒光篩選(測
34、量膜電位)結合試驗 (標記的HERG通道阻滯劑,HTS)斑馬魚HTS結合藥代/藥效,研究毒理學生物標志,預測臨床,安全藥理學研究新技術新方法,,趨勢展望,PART III TISSUE-SPECIFIC MANIPULATIONSNitroreductase-Mediated Cell Ablation in Transgenic Zebrafish EmbryosFocal
35、Electroporation in Zebrafish Embryos and LarvaeTissue Micromanipulation in Zebrafish Embryos,計算機模擬 (in silico)干細胞定向分化為心肌細胞下丘腦病理切片HERG通道體外篩選新方法熒光篩選(測量膜電位)結合試驗 (標記的HERG通道阻滯劑,HTS)斑馬魚HTS結合藥代/藥效,研究毒理學生物標志,預測臨床,安全藥理學研究
36、新技術新方法,,趨勢展望,PART IV ANALYZING GENE EXPRESSIONZebrafish Spotted-Microarray for Genome-Wide Expression Profiling Experiments. Part I: Array Printing and HybridizationPart II : Data Acquisition and AnalysisValidating m
37、icroRNA Target Transcripts Using Zebrafish Assays,計算機模擬 (in silico)干細胞定向分化為心肌細胞下丘腦病理切片HERG通道體外篩選新方法熒光篩選(測量膜電位)結合試驗 (標記的HERG通道阻滯劑,HTS)斑馬魚HTS結合藥代/藥效,研究毒理學生物標志,預測臨床,安全藥理學研究新技術新方法,,趨勢展望,PART V IMAGINGMultiple Embryo
38、Time-Lapse Imaging of Zebrafish Development Live Cell Imaging of Zebrafish LeukocytesImaging Zebrafish Embryos by Two-Photon Excitation Time-Lapse MicroscopyMorphological Analysis of the Zebrafish Digestive SystemIn
39、Toto Imaging of Embryogenesis with Confocal Time-Lapse Microscopy,High sensitivityHigh concentration in myocardium after myocardial injuryRapid release for early diagnosisLong half-life in blood for late diagnosisHi
40、gh specificityAbsent in non-myocardial tissuesNot detectable in blood of non-diseased subjects,生物標志物,,Ideal Cardiac Biomarker,Analytical characteristicsMeasurable by cost-effective assaySimple to performRapid turnar
41、ound timeSufficient precision and truenessClinical characteristicsAbility to influence therapyAbility to improve patient outcome,生物標志物,,Ideal Cardiac Biomarker,Biomarkers of cardiac disease,生物標志物,趨勢展望,小 結,,New, R
溫馨提示
- 1. 本站所有資源如無特殊說明,都需要本地電腦安裝OFFICE2007和PDF閱讀器。圖紙軟件為CAD,CAXA,PROE,UG,SolidWorks等.壓縮文件請下載最新的WinRAR軟件解壓。
- 2. 本站的文檔不包含任何第三方提供的附件圖紙等,如果需要附件,請聯(lián)系上傳者。文件的所有權益歸上傳用戶所有。
- 3. 本站RAR壓縮包中若帶圖紙,網(wǎng)頁內容里面會有圖紙預覽,若沒有圖紙預覽就沒有圖紙。
- 4. 未經(jīng)權益所有人同意不得將文件中的內容挪作商業(yè)或盈利用途。
- 5. 眾賞文庫僅提供信息存儲空間,僅對用戶上傳內容的表現(xiàn)方式做保護處理,對用戶上傳分享的文檔內容本身不做任何修改或編輯,并不能對任何下載內容負責。
- 6. 下載文件中如有侵權或不適當內容,請與我們聯(lián)系,我們立即糾正。
- 7. 本站不保證下載資源的準確性、安全性和完整性, 同時也不承擔用戶因使用這些下載資源對自己和他人造成任何形式的傷害或損失。
評論
0/150
提交評論